2022 / 02

Next Paper
DOI: 10.47183/mes.2022.020

ORIGINAL RESEARCH

Dynamics of humoral immunity to SARS-CoV-2 in the professionally homogeneous group of people over a two-year period of COVID-19 outbreak

Pomelova VG, Bychenkova TA, Bekman NI, Osin NS, Ishkov YuN, Styazhkin KK
About authors

State Research Institute of Biological Instrumentation of the Federal Medical Biological Agency, Moscow, Russia

Correspondence should be addressed: Vera G. Pomelova
Volokolamskoe shosse, 75, corp. 1, Moscow, 125424, Russia; ur.neercsonummi@avolemop.v

About paper

Acknowledgements: we would like to thank staff members of the State Research Institute of Biological Instrumentation: Kanaeva TA for carrying out immunochipbased analysis, Balaban AS for antigen printing with nanoplotter and immunochip preparation for analysis, Stadnik OB for management of the serum samples acquisition and testing using commercially available immunoassay kit.

Author contribution: Pomelova VG — concept, experimental design, manuscript writing; Bychenkova TA — management of immunochip-based immunochemistry studies, data processing; Bekman NI — statistical analysis, preparation of illustrations; Osin NS — providing technical assistance, data analysis and discussion, manuscript editing; Ishkov YuN, Styazhkin KK — data analysis and discussion, manuscript editing.

Compliance with ethical standards: the study was approved by the Ethics Committee of the State Research Institute of Biological Instrumentation (protocol № 4 dated June 09, 2021). The informed consent was submitted by all subjects.

Received: 2022-05-19 Accepted: 2022-06-04 Published online: 2022-06-16
|
  1. Popova AYu, Ezhlova EB, Melnikova AA, Andreeva EE, Kombarova SYu, Lyalina LV, i dr. Kollektivnyj immunitet k SARS-CoV-2 zhitelej Moskvy v ehpidemicheskij period COVID-19. Infekcionnye bolezni. 2020; 18 (4): 8–16. DOI: 10.20953/1729-9225-2020-48-16. Russian.
  2. Ahmed ZB, Razu MH, Akter F, Rabby RI, Karmaker P, Kha M. Seropositivity of SARS-CoV-2 IgG Antibody among People in Dhaka City during the Prevaccination Period. Hindawi BioMed Research International. 2022; 2022: 6. Available from: https://doi. org/10.1155/2022/4451144.
  3. Santiago L, Uranga-Murillo I, Arias M, González-Ramírez AM, Macías-León J, Moreo E, et al. Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2. Biology. 2021; 10: 208. Available from: https://doi.org/ 10.3390/biology10030208.
  4. Karmishin AM., Nosov NYu, Postupajlo VB, Zhigarlovskij BA, Kruglov AA, Petuxov AN. Method for quantitative assasment of protective immunity against SARS-COV-2, its duration and antibody dynamics. Extreme Medicine. 2021; 2 (23): 5–12. DOI: 10.47183/mes.2021.019. Russian.
  5. Dan JM, Mateus J, Kato Yu, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021; 371: eabf4063 (2021). DOI: 10.1126/science.abf4063.
  6. Huang B, Cai Yu, Li N, Li K, Wang Z, Li L, et al. Sex-based clinical and immunological differences in COVID-19. BMC Infectious Diseases. 2021; 21: 647. Available from: https://doi.org/10.1186/ s12879-021-06313-2.
  7. Schlickeiser S, Schwarz T, Steiner S, Wittke K, Al Besher N, Meyer O, et al. Disease severity, fever, age, and sex correlate with SARS-CoV-2 neutralizing antibody responses. Front Immunol. 2021; 11: 628971. DOI: 10.3389/fimmu.2020.628971.
  8. Naaber P, Tserel L, Kangro K, Sepp E, Jürjenson V, Adamson A, et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. The Lancet Regional Health — Europe. 2021; 10: 1–10. Available from: https://doi. org/10.1016/j.lanepe.2021.100208.
  9. Markewitz R, Torge A, Wandinger K-P, Pauli D, Franke A, Bujanda L, et al. Clinical correlates of anti SARS CoV 2 antibody profiles in Spanish COVID 19 patients from a high incidence region. Scientifc Reports. 2021; 11: 4363. Available from: https://doi.org/10.1038/ s41598-021-83969-5.
  10. Li C, Yu D, Wu X, Liang H, Zhou Z, Xie Y, et al. Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan. Nature Communications. 2021; 12: 4846. Available from: https:// doi.org/10.1038/s41467-021-25109-1 | www.nature.com/ naturecommunications.
  11. Pomelova VG, Korenberg EI, Kuznetsova TI, Bychenkova TA, Bekman NI, Osin NS. C6 Peptide-Based Multiplex Phosphorescence Analysis (PHOSPHAN) for Serologic Confirmation of Lyme Borreliosis. PLoS ONE. 2015; 10 (7): e0130048. DOI: 10.1371/ journal.pone.0130048.
  12. Bekman NI, Pomelova VG, Osin NS. Mul'tipleksnyj analiz narkoticheskix sredstv na osnove texnologii immunochipov FOSFAN. Klinicheskaya laboratornaya diagnostika. 2018; 63 (3): 178–83. Available from: http://dx.doi.org/10.18821/0869-20842018-63-3-178-183. Russian.
  13. Bekman NI, Laricheva SYu, Bychenkova TA, Pomelova VG, Osin NS. Odnovremennoe opredelenie tireotropnogo gormona i svobodnogo tiroksina v suxix pyatnax krovi cheloveka s ispol'zovaniem fosforescentnyx nanochastic. Bioorganicheskaya ximiya. 2020; 46 (2): 170–9. DOI: 10.31857/s0132341320020074. Russian.
  14. Markmann AJ, Giallourou N, Bhowmik DR, Hou YJ, Lerner A, Martinez DR. et al. Sex disparities and neutralizing-antibody durability to SARS-CoV-2 infection in convalescent individuals. mSphere. 2021; 6: e00275-21. Available from: https://doi. org/10.1128/mSphere.00275-21.
  15. Zeng F, Dai C, Cai P, Wang J, Xu L, Li J, et al. A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: A possible reason underlying different outcome between sex. J Med Virol. 2020; 1–5. DOI: 10.1002/jmv.25989.
  16. Statistika koronavirusa v Moskve. Dostupno po ssylke: http://russian-trade.com/coronavirus-russia/Moskva. Russian.
  17. Knorre DD, Nabieva E, Garushyanc SK. Rossijskij konsorcium po sekvenirovaniyu genomov koronavirusov (CORGI). Dostupno po ssylke: http://taxameter.ru. Russian.
  18. Logunov DY, Dolzhikova IV, Zubkova OV, Tuchvatullin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase — studies from Russia. The Lancet. 2020; 396 (10255): 887–97. Available from: https://doi.org/10.1016/ S0140-6736(20)31866-3.
  19. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tuchvatullin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an RAD26 and RAD5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet. 2021; 397 (10275): 671. Available from: https://doi.org/10.1016/S0140-6736(21)00234-8.
  20. Kolobuxina LV, Burgasova OA, Kruzhkova IS, Bakalin VV, Generalova LV, Shagaev AV, i dr. Ocenka klinicheskogo techeniya COVID-19 u pacientov, vakcinirovannyx «Sputnik V», izmenchivosti RBD-domena S-belka SARS-COV-2 i virusnejtralizuyushhix svojstv syvorotki. Vestnik RGMU. 2021; 5: 66–75. DOI: 10.24075/ vrgmu.2021.046. Russian.
  21. Gushchin VA, Dolzhikova IV, Shchetinin AM, Odintsova AS, Siniavin AE, Nikiforova MA, et al. Neutralizing activity of sera from Sputnik V-vaccinated people against variants of concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow endemic SARS-CoV-2 variants. Vaccines. 2021; 9: 779. Available from: https://doi.org/10.3390/vaccines9070779.
  22. Garafutdinov RR, Mavzyutov AR, Nikonorov YuM, Chubukova OV, Matniyazov RT, Bajmiev AnX, i dr. Betakoronavirus SARSCoV-2, ego genom, raznoobrazie genotipov i molekulyarnobiologicheskie mery bor'by s nim. Biomika. 2020; 12 (2): 242–71. DOI: 10.31301/2221-6197.bmcs.2020-15. Russian.
  23. Borisova NI, Kotov IA, Kolesnikov AA, Kaptelova VV, Speranskaya AS, Kondrasheva L.u, i dr. Monitoring rasprostraneniya variantov SARS-CoV-2 (Coronaviridae: Coronavirinae: Betacoronavirus; Sarbecovirus) na territorii Moskovskogo regiona s pomoshh'yu targetnogo vysokoproizvoditel'nogo sekvenirovaniya. Voprosy virusologii. 2021; 66 (4): 269–78. DOI: https://doi.org/10.36233/0507-408872. Russian.
  24. Wu J, Tang L, Ma Y, Zhang D, Li Q, Mei H, Hu Y. Immunological profiling of COVID-19 patients with pulmonary sequelae. 2021; mBio 12: e01599-21. Available from: https://doi.org/10.1128/mBio.01599-21.
  25. Grossberg AN, Koza LA, Ledreux A, Prusmack C, Krishnamurthy HK, Jayaraman V, et al. A multiplex chemiluminescent immunoassay for serological profiling of COVID-19-positive symptomatic and asymptomatic patients. Nature Communications. 2021; 12: 740. Available from: https://doi.org/10.1038/s41467-021-21040-7.